Please assess the completion status of the following clinical trial:

Trial Title: Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Evidence of intracranial hemorrhage (bleeding in the brain) by CT scan related to traumatic injury~* Receiving antiplatelet therapy such as aspirin, thienopyridine (ticlopidine, clopidogrel, or prasugrel)~* Platelet count greater than or equal to 100,000~Exclusion Criteria:~* Glasgow Coma Scale (GCS) less than 6~* Hemorrhage requiring emergent surgery~* Lack of permission from treating physician and/or consultant~* Secondary ICH related to aneurysm or arteriovenous malformation~* Use of oral anticoagulants~* Decreased platelets (thrombocytopenia)~* Patients requiring massive transfusion protocol~* Life expectancy less than 3 months~* Confirmed acute heart attack~* Hepatitis and liver cirrhosis~* Kidney failure~* Participation in another treatment study within the preceding 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Saline (Type: PLACEBO_COMPARATOR): 400 mL of Saline will be given intravenously over 2 hours once.
- Platelets (Type: ACTIVE_COMPARATOR): 2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).